Atrogi’s technology platform, building upon the idea of stimulating the β2-adrenergic receptor in a novel way, is designed to target a range of metabolic disorders, including diabetes, obesity, and muscle-wasting conditions.
With proprietary compounds currently in preclinical testing for obesity and muscular wasting, we are committed to transforming the way these conditions are treated.
We are also developing a first-in-class, insulin-independent therapy for type 2 diabetes that works through the same mechanism. By selectively modulating cellular processes that transport glucose from the blood into skeletal muscles, this approach offers durable glycemic control, providing a groundbreaking alternative for patients.
Our lead asset, ATR-258, has completed a successful Phase I safety study in both healthy volunteers and individuals with type 2 diabetes. This once-daily, synthetic small molecule provides substantial advantages in patient adherence and convenience over injectable therapies. Additionally, its straightforward, scalable formulation supports a lower cost of goods, making it not only a patient-friendly option but also a commercially viable solution.
Diabetes is a growing global epidemic. Already, over half a billion people are living with diabetes worldwide, which is over 10.5% of the world’s adult population, and around 1.5 million deaths are directly attributed to diabetes each year1, 2. A typical individual has around a 30% risk of developing T2D. The shortened lifespan of diabetic patients can be attributed directly or indirectly to the dysfunctional regulation of blood glucose levels.
This epidemic is not just a major problem for patients, who often suffer from cardiovascular problems, blindness, kidney failure and muscular atrophy, but also a major burden for health care systems around the world, as diabetes treatment represents a significant percentage of total global health expenditure. The world needs a revolutionary new solution that is effective, reliable, and safe, that can help patients have a better quality of life.
Our lead asset, ATR-258 has successfully completed a Phase I trial in healthy volunteers (n=48) and type 2 diabetes patients (n=24). Phase 2 clinical trials with ATR-258 is planned to start in 2025.
Obesity isn’t just a growing epidemic—it’s a global health crisis projected to affect over half the world’s population by 2035. At its core, obesity results from an imbalance in metabolism and the impact is profound, not only on individuals’ health but also on the financial strain placed on healthcare systems worldwide. The need for innovative, effective solutions has never been greater.
At Atrogi we are pioneering a revolutionary approach to obesity treatment. Our cutting-edge pipeline focuses on metabolic disorders, with a novel drug candidate designed to restore proper metabolic function without the muscle atrophy often caused by conventional treatments. Currently in pre-clinical development, our small molecule therapy has shown promising potential to increase metabolism and promote fat loss, while preserving muscle mass, positioning it as a powerful new solution in the fight against obesity.
We are on track to selecting a lead candidate for further clinical development in early 2025, advancing our commitment to innovative and effective treatments for affected patients.
Through our cutting-edge technology platform, we are pioneering the development of novel therapeutic β2-adrenergic agonists aimed at combating muscle wasting. This debilitating condition, commonly seen in diabetic patients and the aging population, as well as in a number of rare genetic diseases, significantly impacts quality of life for those affected.
Our team is advancing a breakthrough compound specifically designed to address muscle deterioration. In pre-clinical models of progressive muscular atrophy, this compound has demonstrated not just improvements but transformative effects on muscle mass and function—showcasing a potential far beyond current treatment options.
With these promising results, we are moving forward to advance this project and plan to select a lead candidate for clinical development, bringing us one step closer to delivering a much-needed solution to those affected by muscle-wasting disorders.
